NCT00310830View on ClinicalTrials.gov

Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)

PHASE3TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Pulmonary Hypertension
Interventions
DRUG

Bosentan

Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.

Sponsors

Lead Sponsor

Actelion
All Listed Sponsors
lead

Actelion

INDUSTRY